PHIO Pharmaceuticals reports full enrollment in PH-762 Phase 1b trial

Rhea-AI Filing Summary

PHIO Pharmaceuticals Corp. reported that it has completed enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of its INTASYL siRNA lead compound, PH-762. This means all planned participants have been enrolled and the study can now proceed using the full patient group for evaluation. The update was shared through a press release dated November 25, 2025, which is included as an exhibit to this report.

Insights

Biotech clinical development analyst

PHIO completes enrollment in a Phase 1b trial for lead drug PH-762.

PHIO Pharmaceuticals announced completion of enrollment in an ongoing Phase 1b trial (NCT 06014086) of its INTASYL siRNA lead compound PH-762. Completion of enrollment typically marks the point where the full planned patient group has entered the study, allowing data collection to proceed on the intended scale.

Because this is an early-stage clinical trial, the announcement focuses on operational progress rather than efficacy or safety outcomes. No financial terms or study results are provided, so the immediate implications relate to trial execution rather than commercial impact.

The next meaningful developments are likely to come from future disclosures of clinical data or subsequent trial stages, which are not detailed here. For now, this update mainly signals that the company has reached a planned milestone in the PH-762 development program.

false 0001533040 0001533040 2025-11-25 2025-11-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  November 25, 2025

PHIO PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware	001-36304	45-3215903
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

411 Swedeland Road, Suite 23-1080
King of Prussia, PA	19406
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (610) 947-0251

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
Common Stock, par value $0.0001 per share		PHIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On November 25, 2025, the Company issued a press release announcing the completion of enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of INTASYL siRNA Lead Compound PH-762.

The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by the Company on November 25, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHIO PHARMACEUTICALS CORP.
Date: November 25, 2025	By:	/s/ Robert J. Bitterman
		Robert J. Bitterman President & Chief Executive Officer

3

FAQ

What did PHIO Pharmaceuticals (PHIO) announce in this 8-K filing?

PHIO Pharmaceuticals announced that it has completed enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of its INTASYL siRNA lead compound PH-762.

Which clinical trial is mentioned for PHIO Pharmaceuticals' PH-762?

The filing refers to an ongoing Phase 1b clinical trial of PH-762, identified as NCT 06014086.

What stage of development is PH-762 in according to PHIO's 8-K?

PH-762 is being studied in an ongoing Phase 1b clinical trial, indicating it is in early-stage clinical development.

How did PHIO Pharmaceuticals communicate the enrollment milestone for PH-762?

The company issued a press release on November 25, 2025, and that release is attached to the report as Exhibit 99.1.

Does the PHIO 8-K filing include clinical results for PH-762?

No clinical results are described in this report; it only states that enrollment has been completed in the Phase 1b trial of PH-762.

What exhibits are attached to the PHIO Pharmaceuticals 8-K?

The filing includes Exhibit 99.1, the press release about PH-762, and Exhibit 104, the cover page interactive data file.